AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03931642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCHOP
Description: D1 : Rituximab 375 mg/m² IV + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.~From D1 to D5 : Prednisone 60 mg/m² PO.
Study NCT03931642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab by continuous vein infusion
Study NCT02608502 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV-F Vaccine
Study NCT02608502 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffer Placebo
Study NCT00401778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAD001
Description: Patients will be assigned to one of three treatment arms with RAD001 doses of 5, and 10 mg/day for 21-28 days sequentially taken orally in tablet form.
Study NCT01536626 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Prescription at the discretion of the treating physician
Study NCT02930005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meclofenamic acid
Study NCT02930005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium
Study NCT01001208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate tablets over-encapsulated for blinding
Study NCT01001208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 1 mL for subcutaneous injection
Study NCT01001208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: 1 mL for subcutaneous injection
Study NCT01001208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo to methotrexate capsules
Study NCT01780415 — intervention group
Intervention type: OTHER
Intervention: blastocoele aspiration
Study NCT01767064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posted commitment letter
Study NCT03319420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LO2A eye drops
Description: Sodium hyaluronate
Study NCT03319420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra UD
Description: Active Ingredients; Polyethylene Glycol Propylene Glycol
Study NCT03250533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light emitting diodes (LED)
Description: The light-emitting diode (LED) device consists of a soft 15 x 15 cm blanket, which allows the body segment curvature of the cutaneous lesion to be monitored. The LEDs are fixed equidistant to obtain uniform irradiation over the entire ulcer. The wound site will be surrounded by a PVC film (polyvinyl chloride), to avoid contamination, for posterior positioning of the LED device, applying light directly and perpendicularly, with energy density of 6 J / cm². All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density.
Study NCT03250533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed diphasic current
Description: The electrical stimulation treatment will be performed with the fixed diphasic current of the Dualpex 071 equipment (Quark®, Piracicaba, SP, Brazil), with the monopolar technique, 100 Hz, maximum intensity of 1 mA / cm² of lesion for 10 minutes. Autoclave sterilized aluminum electrodes will be used, one on the lesion (negative pole) and the other transversal to the segment (positive pole). The size of the electrode will be proportional to the extension of the lesion, having as a means of contact between the electrode and the ulcer, sterile gauze moistened with 0.9% saline solution.
Study NCT01265784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-434
Study NCT01265784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Study NCT01265784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered IV to maintain the blind.
Study NCT01265784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered IV to maintain the blind.
Study NCT00421005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvastatin
Description: Fluvastatin 80 mg (Arm 1) vs. Fluvastatin 20 mg (Arm 2) increased according with LDL concentrations
Study NCT00421005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluvastatin
Description: Fluvastatin 80 mg (Arm 1) vs. Fluvastatin 20 mg (Arm 2) increased according with LDL concentrations
Study NCT00883090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FXIII Concentrate (Human)
Description: Subjects will receive approximately 40 U/kg of FXIII every 28 days for 3 doses administered as a bolus intravenous (IV) injection at approximately 250 U/minute.
Study NCT04362397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FoCo
Description: This is an attention, care and self-care training.
Study NCT04362397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No intervention
Description: This is a waiting list
Study NCT01779323 — intervention group
Intervention type: OTHER
Intervention: Pre and Post Sling Pelvic MRI
Description: Pre and Post Sling Pelvic MRI
Study NCT01333527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Sling
Description: Early range of motion
Study NCT01333527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sling
Description: Patients will use the sling for 6 weeks, as per usual care
Study NCT02304432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
Study NCT02304432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCS or placebo
Description: Double-blind placebo-controlled exposures to DCS or placebo x 6 weeks. One participant received exposure to DCS x 6 weeks and then received placebo dosing x 6 weeks. The other participant received exposure to placebo dosing x 6 weeks and then DCS x 6 weeks.
Study NCT02304432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: Both participants received second open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
Study NCT04453202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine
Description: Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.
Study NCT04453202 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single IM injection of placebo on Day 1.
Study NCT04453202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single IM injection of placebo on Day 1.
Study NCT03031054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sono-guided injection with hyaluronic acid
Description: Sono-guided injection with hyaluronic acid (ARTZDispo, 25 mg/2.5 ml) between carpal tunnel and median nerve
Study NCT03031054 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sono-guided injection with normal saline
Description: Sono-guided injection with 2.5cc Normal saline (0.9%) between carpal tunnel and median nerve
Study NCT01400425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: IV injection, 370 megabecquerel (MBq) (10 millicurie \[mCi\]), single dose
Study NCT00235456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative supplemental oxygen
Description: Patients were assigned to 80% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
Study NCT00235456 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard oxygen
Description: Patients were assigned to 30% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
Study NCT03811080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 A mg
Description: The participants will receive treatment of DWP14012 A mg, tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
Study NCT03811080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 B mg
Description: The participants will receive treatment of DWP14012 B mg, tablet, orally, once daily and DWP14012 A mg placebo-matching tablet, orally, once daily for up to 4 weeks.
Study NCT03811080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will receive treatment of DWP14012 A mg placebo-matching tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
Study NCT03394209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: In first step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1600 mg twice daily. Starting from the second day, the dosage is 600 mg twice daily.~In second step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1800 mg twice daily. Starting from the second day, the dosage is 800 mg twice daily.
Study NCT03394209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75Mg Capsule
Description: oseltamivir will be administered at 75mg twice daily orally for 10 days
Study NCT03536624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6 days spa residential program
Description: 6 days spa residential program combining psychological intervention, physical activity, thermal spa treatment, health education and corrections of eating disorders.
Study NCT03231956 — intervention group
Intervention type: DEVICE
Intervention: ClearSight™ / EV1000NI Clinical Platform
Description: Noninvasive Hemodynamic Monitoring utilizing ClearSight TM System
Study NCT01994525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfRAS
Description: Radiation-attenuated Plasmodium falciparum sporozoites (PfRAS) administered by the bite of infected Anopheles stephensi mosquitoes
Study NCT01994525 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by the bite of noninfected Anopheles stephensi mosquitoes
Study NCT01994525 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Challenge
Description: 5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.
Study NCT01994525 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Challenge
Description: 5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.
Study NCT01994525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Challenge
Description: 5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.
Study NCT00733616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOX: Docetaxel, oxaliplatin, Capecitabine
Description: * Docetaxel 40 mg/m2, iv infusion 60 minutes, day 1~* Oxaliplatin 80 mg/m2, iv infusion 120 minutes, day 1~* Capecitabine 625 mg/m2, bid, oral, continuous~  6 cycles, every 3 weeks~Capecitabine will be given same dose (625mg/m2/bid) continuous in case no toxicity (no dose adjustment)
Study NCT04015232 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: INTP5
Description: INTP5, a pegfilgrastim biosimilar to US Neulasta.
Study NCT04015232 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: US Neulasta
Description: US Neulasta: FDA approved pegfilgrastim innovator product.
Study NCT03473314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide gas at 160ppm
Description: Nitric oxide gas at 160 ppm inhaled three times daily for 50-80 min delivered with air as the carrier via inhalation for a maximum total of 90 days (extended 365 days twice). Total dose of 480 ppm hours per day.
Study NCT02658084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Administered as an intravenous infusion on Day 1 and Day 8 of every 21-day cycle.
Study NCT02658084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Administered as an intravenous infusion on Day 1 of every 21-day cycle.
Study NCT01880073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemVue device
Description: The device will be used in conjunction with what is now considered the standard of care to determine if it's as effective.
Study NCT02933775 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CAR-CD19 T cells
Description: Initial dose: A total of 1 - 10×10\^7 CAR-CD19 T cells/kg will be administered by 1 - 3 infusions. Subsequent dose will be based on the subject's response to initial dose.
Study NCT02933775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2/day×4 days
Study NCT02933775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2/day×2 days
Study NCT01153984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg oral doses will be administered daily.
Study NCT02857842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Study NCT02857842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Study NCT03247556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered once daily
Study NCT03247556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400mg SPN-812
Description: 400mg SPN-812 was administered once daily and compared to Placebo
Study NCT03247556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600mg SPN-812
Description: 600mg SPN-812 was administered once daily and compared to Placebo
Study NCT04148313 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study.
Study NCT03057392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion
Description: participants will sit in a 34-35C while receive dialysis
Study NCT03057392 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham session
Description: dialysis while sitting in the dialysis chair
Study NCT02495558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflex Cough Test
Description: Peak of Cough Expiratory Flow of the reflex cough
Study NCT04614961 — intervention group
Intervention type: OTHER
Intervention: Lifestyle therapy - individual
Description: Individual therapy
Study NCT04614961 — intervention group
Intervention type: OTHER
Intervention: Lifestyle therapy - group
Description: Group therapy
Study NCT04614961 — intervention group
Intervention type: OTHER
Intervention: Medical therapy
Description: Medical therapy
Study NCT04614961 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Surgical and endoscopic therapy
Study NCT03413046 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral and bone marrow sampling
Description: We obtained blood from peripheral and bone marrow sampling. Then we analyze Treg population and Treg related cytokines with flow cytometry and ELISA methods.
Study NCT03654196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL301(Experimental)
Description: Total 7 days of treatment and The daily dose is as follows \[Morning: HL301 1Tab + Placebo of Umkamin 1Tab\] \[Noon: Placebo of Umkamin 1Tab\] \[Evening: HL301 1Tab + Placebo of Umkamin 1Tab\]
Study NCT03654196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Umkamin(Active Comparator)
Description: Total 7 days of treatment and The daily dose is as follows \[Morning: Placebo of HL301 1Tab + Umkamin 1Tab\] \[Noon: Umkamin 1Tab\] \[Evening: Placebo of HL301 1Tab + Umkamin 1Tab\]
Study NCT03717064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7049389
Description: RO7049389 will be taken orally, in tablet form, BID on Days 1-6 of Period 2.
Study NCT03717064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin will be taken orally, in tablet form, once on Day 1 of Period 1, and once on Day 4 of Period 2.
Study NCT00430079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanidazole
Description: Given IV
Study NCT00430079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo surgery
Study NCT00430079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00430079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00337077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Given IV
Study NCT02305758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: 200 mg oral dose beginning 2 days prior to the start of FOLFIRI and continuing twice a day (BID) for a total of 7 consecutive days
Study NCT02305758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg oral dose beginning 2 days prior to the start of FOLFIRI and continuing twice a day (BID) for a total of 7 consecutive days
Study NCT02305758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRI
Description: Irinotecan 180 mg/m\^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m\^2 (90-minute infusion ± 30 minutes); and saline bolus (up to 15-minute infusion) on Day 1 of each 14-day cycle
Study NCT02305758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFIRI
Description: Irinotecan 180 mg/m\^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m\^2 (90-minute infusion ± 30 minutes); and fluorouracil bolus 400 mg/m\^2 (up to 15-minute infusion) on Day 1 of each 14-day cycle
Study NCT02305758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: At the discretion of the Investigator, 5 mg/kg may be administered intravenously immediately preceding FOLFIRI dosing
Study NCT02305758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: At the discretion of the Investigator, 5 mg/kg may be administered intravenously immediately preceding FOLFIRI dosing
Study NCT02305758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluorouracil infusion
Description: 2400 mg/m\^2 (46-hour continuous infusion ± 4 hours) starting on Day 1 of each 14-day cycle
Study NCT02305758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil infusion
Description: 2400 mg/m\^2 (46-hour continuous infusion ± 4 hours) starting on Day 1 of each 14-day cycle
Study NCT05249413 — intervention group
Intervention type: PROCEDURE
Intervention: Early 23-gauge pars-plana vitrectomy
Description: pars-plana vitrectomy for management of acute post-operative endophthalmitis.
Study NCT03831048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCS Heart System
Description: Preserving and assessing donor after circulatory death hearts for transplant
Study NCT03831048 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Storage
Description: Active comparator intervention
Study NCT03102580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OA Care Plan
Description: Patient and surgeon will receive the OA Care Plan (currently under development). This Care Plan will inform Shared Decision for treatment of moderate to sever OA, including surgical and non-surgical options.
Study NCT02761980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 250 mg / Acetaminophen 500 mg
Description: Ibuprofen 250 mg / Acetaminophen 500 mg
Study NCT02761980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 250 mg
Description: Ibuprofen 250 mg
Study NCT02761980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 500 mg
Description: 1 APAP 500 mg caplet
Study NCT02761980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT00826774 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in this group will receive usual medical care, provided by their own primary care providers (PCPs). PCPs also will provide participants recommendations for weight management at quarterly-scheduled visits.
Study NCT00826774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Lifestyle Counseling
Description: These participants, like those in the Usual Care group, will receive the same PCP visits, plus monthly brief counseling sessions with an auxiliary health care provider (e.g., a medical assistant), on-site or by phone.